VOSPIRE ER Rx
Generic Name and Formulations:
Albuterol (as sulfate) 4mg; ext-rel tabs.
DAVA Pharmaceuticals, Inc.
Indications for VOSPIRE ER:
Swallow whole. 4–8mg every 12 hours; max 32mg/day in 2 divided doses (every 12 hours).
Swallow whole. <6yrs: not recommended. ≥6yrs: 4mg every 12 hours; max 24mg/day in 2 divided doses.
Avoid excessive use. Sensitivity to sympathomimetics. Discontinue if paradoxical bronchospasm or cardiovascular effects occur. Cardiovascular disease (eg, coronary insufficiency, arrhythmias, hypertension). Diabetes. Hyperthyroidism. Seizure disorders. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Avoid MAOIs, tricyclics within 14 days (increased cardiovascular effects). Oral sympathomimetics: not recommended. Antagonized by β-blockers. Monitor digoxin. Caution with other drugs that lower serum potassium.
Tremor, headache, nervousness, GI upset, tachycardia, muscle cramps, insomnia, dizziness, somnolence, weakness, CNS stimulation, difficulty in micturition, hypokalemia, paradoxical bronchospasm, rash.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds